{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06457997",
            "orgStudyIdInfo": {
                "id": "PHN-010-001"
            },
            "organization": {
                "fullName": "Pheon Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of PHN-010 in Patients With Advanced Solid Tumors",
            "officialTitle": "First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-phn-in-patients-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-06",
            "studyFirstSubmitQcDate": "2024-06-11",
            "studyFirstPostDateStruct": {
                "date": "2024-06-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pheon Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Lung Cancer",
                "Colon Cancer",
                "Endometrial Cancer",
                "Ovarian Cancer",
                "Cervical Cancer",
                "Advanced Solid Tumor",
                "Advanced Cancer"
            ],
            "keywords": [
                "Antibody-Drug Conjugate",
                "Carcinoma",
                "Cancer",
                "Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 273,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1a and Phase 1b",
                    "type": "EXPERIMENTAL",
                    "description": "PHN-010 is administered intravenously.",
                    "interventionNames": [
                        "Drug: PHN-010"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PHN-010",
                    "description": "PHN-010 is an ADC",
                    "armGroupLabels": [
                        "Phase 1a and Phase 1b"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of dose limiting toxicities (Phase 1a)",
                    "timeFrame": "18 months"
                },
                {
                    "measure": "Type, incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Phase 1a)",
                    "timeFrame": "18 months"
                },
                {
                    "measure": "Frequency of dose interruptions, reductions, and discontinuations (Phase 1a and 1b)",
                    "timeFrame": "18 months"
                },
                {
                    "measure": "Overall response rate (ORR) (Phase 1b)",
                    "timeFrame": "36 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Best overall response (BOR) (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Disease control rate (DCR) (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Progression free survival (PFS) (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Time to response (TTR) (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Overall survival (OS) (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Cancer antigen 125 (CA-125) response (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Time to CA-125 response (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, maximum concentration (Cmax) of total ADC (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, Cmax of total antibody (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, Cmax of free payload (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, time of Cmax (Tmax) of total ADC (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, Tmax of total antibody (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, Tmax of free payload (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, area under the curve (AUC) of total ADC (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, AUC of total antibody (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, AUC of total free payload (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, terminal half-life (t1/2) of total ADC (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, t1/2 of total antibody (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Pharmacokinetics, t1/2 of free payload (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Concentration of anti-drug antibodies (Phase 1a and 1b)",
                    "timeFrame": "36 months"
                },
                {
                    "measure": "Type, incidence and severity of AEs and SAEs (Phase 1b)",
                    "timeFrame": "18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Has histologically confirmed, advanced/metastatic:\n\n  1. Colorectal adenocarcinoma (CRC), or\n  2. Serous, endometroid, or clear-cell epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, or\n  3. Serous, endometroid or clear-cell endometrial cancer, or\n  4. Adenocarcinoma or squamous-cell carcinoma of the cervix, or\n  5. Non-small cell lung cancer (NSCLC).\n* Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy.\n* Has measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has adequate organ function.\n* Has available tumor tissue sample at screening (either an archival specimen collected \u2264 3 years prior to the date of informed consent or fresh biopsy material).\n\nExclusion Criteria:\n\n* Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload.\n* Has unstable central nervous system metastasis.\n* Has persistent toxicities from previous systemic anti-cancer treatments of Grade \\>1.\n* Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.\n* Has received wide-field radiotherapy (\\> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Has acute and/or clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV).\n* Has a history of non-infectious pneumonitis (NIP) / interstitial lung disease (ILD) requiring systemic steroids, active NIP / ILD or suspected NIP / ILD which cannot be ruled out by imaging for Screening.\n\nOther protocol defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Myles Clancy",
                    "role": "CONTACT",
                    "phone": "617-304-4950",
                    "email": "PHN010001trial@pheontx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "844-482-4812"
                        },
                        {
                            "name": "Vivek Subbiah, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "NEXT - San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ildefonso Ismael Rodriguez, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "NEXT - Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "M. Adham Salkeni, MD, FRCPC",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M26725",
                    "name": "Neuralgia, Postherpetic",
                    "relevance": "LOW"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}